Affordable Access

Acute coronary syndrome induced by capecitabine therapy.

Authors
  • Wijesinghe, Namal
  • Thompson, Paul I
  • McAlister, Hugh
Type
Published Article
Journal
Heart, lung & circulation
Publication Date
Oct 01, 2006
Volume
15
Issue
5
Pages
337–339
Identifiers
PMID: 16697705
Source
Medline
License
Unknown

Abstract

Capecitabine, a new member of the fluoropyrimidine family, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumour. Although the cardiotoxicity of 5-FU is well documented, there is little published data about cardiovascular adverse effects of Capecitabine. This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.

Report this publication

Statistics

Seen <100 times